コンテンツへスキップ
Merck

Long-term alcohol and caffeine intake and risk of sudden cardiac death in women.

The American journal of clinical nutrition (2013-04-26)
Monica L Bertoia, Elizabeth W Triche, Dominique S Michaud, Ana Baylin, Joseph W Hogan, Marian L Neuhouser, Matthew S Freiberg, Matthew A Allison, Monika M Safford, Wenjun Li, Yasmin Mossavar-Rahmani, Milagros C Rosal, Charles B Eaton
要旨

Alcohol and caffeine intakes may play a role in the development of sudden cardiac death (SCD) because of their effects on cholesterol, blood pressure, heart rate variability, and inflammation. Our objective was to examine the association between long-term alcohol and caffeine intakes and risk of SCD in women. We examined 93,676 postmenopausal women who participated in the Women's Health Initiative Observational Study. Women were enrolled between 1993 and 1998 and were followed until August 2009. Women completed a food-frequency questionnaire at baseline and again at year 3. We modeled exposure to alcohol 3 ways: by using baseline intake only, a cumulative average of baseline and year 3 intake, and the most recent reported intake (a simple time-varying analysis). Intake of 5-15 g alcohol/d (about one drink) was associated with a nonsignificantly reduced risk of SCD compared with 0.1-5 g/d of baseline intake (HR: 0.64; 95% CI: 0.40, 1.02), of cumulative average intake (HR: 0.69; 95% CI: 0.43, 1.11), and of most recent intake (HR: 0.58; 95% CI: 0.35, 0.96), with adjustment for age, race, income, smoking, body mass index, physical activity, hormone use, and total energy. No association was found between SCD and total caffeine intake (mg/d) or cups of caffeinated coffee, decaffeinated coffee, and caffeinated tea. Our results suggest that about one drink per day (or 5.1-15 g/d) may be associated with a reduced risk of SCD in this population; however, this association was only statistically significant for a model using the most recent alcohol intake. Total caffeine, regular coffee, decaffeinated coffee, and regular tea intake were not associated with the risk of SCD. This trial was registered at clinicaltrials.gov as NCT00000611.

材料
製品番号
ブランド
製品内容

Supelco
カフェイン, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
カフェイン, powder, ReagentPlus®
Sigma-Aldrich
カフェイン, anhydrous, 99%, FCC, FG
Supelco
融点スタンダード235~237°C, analytical standard
Supelco
カフェイン, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
カフェイン 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
カフェイン, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
カフェイン, Sigma Reference Standard, vial of 250 mg
Sigma-Aldrich
カフェイン, meets USP testing specifications, anhydrous
Supelco
カフェイン 溶液, analytical standard, 1.0 mg/mL in methanol
Supelco
Mettler-Toledo®キャリブレーション用物質ME 18872、カフェイン, traceable to primary standards (LGC)
Sigma-Aldrich
カフェイン, anhydrous, tested according to Ph. Eur.
Sigma-Aldrich
カフェイン, BioXtra
システム適合性用カフェイン, European Pharmacopoeia (EP) Reference Standard
カフェイン, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
カフェイン, SAJ special grade, ≥98.5%